IQVIA vs Saama
Two sponsor side vendors selling agents into clinical development, at very different scales. IQVIA launched a unified agentic platform and marketplace in March 2026 spanning clinical, commercial and real world evidence work, names its infrastructure stack precisely, and has the most developed governance apparatus in this category. Saama is narrower and more specific, automating data quality review and query generation across more than fifteen hundred studies at over fifty sponsors, and it names its own autonomy level for its agents, which is a disclosure almost nothing here offers. Both should be asked which of their several relationships to your data governs which capability, because each is simultaneously a service provider, a data holder and a software vendor, and that ambiguity is where sponsor legal teams get stuck.
- The March 2026 agentic platform spans clinical, commercial and real world evidence operations with a marketplace, and the infrastructure stack is named with unusual precision.
- The governance apparatus is the most developed in this category and includes a concrete architectural control rather than a principles page.
- For a sponsor already working with the organisation across trial operations, the agents arrive inside an existing relationship.
- It names its own autonomy level for its agents, which almost nothing in this index does, so a buyer knows what the system decides on its own.
- Deployment is substantial and long standing across more than fifteen hundred studies at over fifty sponsors, so the platform has met real variety.
- Scope is bounded to sponsor side clinical development from study start through regulatory submission rather than spanning commercial operations too.
Side by Side
| Axis | I IQVIA |
S Saama |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both stand in more than one relationship to sponsor data, as service provider, data holder and software vendor, and neither states plainly which relationship governs which capability, which is the first question a sponsor's legal team will ask. Neither publishes an attestation scoped specifically to the agent platform as distinct from the wider business. Saama publishes a governance framework with nothing measurable behind it and no security attestation. Ask both explicitly whether one sponsor's data improves models serving another, and get the answer in contract rather than in a meeting.